Alnylam Pharmaceuticals Inc (ALNY)
201.66
+0.64 (+0.32%)
USD |
NASDAQ |
Oct 06, 09:54
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 24.20B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 1.35% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 27.40 |
| Price to Book Value | 137.49 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 3.850 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 57.81% |
News
Headline
Wire
Time (ET)
MT Newswires
10/03 11:16
Yahoo
10/03 06:08
Yahoo
09/22 12:17
MT Newswires
09/21 16:11
Events
| DATE | TIME | TYPE | PERIOD | REPORTED EPS |
ESTIMATED EPS |
SURPRISE | |
| 10/28/2022* | -- | Results | Q3 2022 | -- | -1.37 | -- | |
| 10/28/2022* | 08:30 EST | Earnings Call | Q3 2022 | -- | -- | -- | |
| 07/28/2022 | 08:30 EST | Earnings Call | Q2 2022 | -- | -- | -- | |
| 07/28/2022 | -- | Results | Q2 2022 | -2.03 | -1.36 | -49.41% | |
| 04/28/2022 | -- | Results | Q1 2022 | -1.49 | -1.46 | -2.09% | |
| 04/28/2022 | 08:30 EST | Earnings Call | Q1 2022 | -- | -- | -- | |
| 02/10/2022 | -- | Results | Q4 2021 | -1.69 | -1.26 | -34.37% | |
| 02/10/2022 | 08:30 EST | Earnings Call | Q4 2021 | -- | -- | -- |
*Estimated Date/Time
Earnings
Profile
Edit
| Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships. |
| URL | https://www.alnylam.com |
| Investor Relations URL | https://investors.alnylam.com/ |
| HQ State/Province | Massachusetts |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | Mid Cap/Growth |
| Next Earnings Release | Oct. 28, 2022 (est.) |
| Last Earnings Release | Jul. 28, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Dividends
| Dividend Per Share (TTM) | -- |
|
2017
2018
2019
2020
2021
6.00%
4.00%
2.00%
|
|
| Yield to Market | 0.00 |
| Yield to Sector | 0.00 |
| Yield to Industry | 0.00 |
| Last Dividend Amt. | -- |
| Dividend Frequency | -- |
| Last Ex-Dividend Date | -- |
| Yield (TTM) | 0% |
| Forward Yield | -- |
| Payout Ratio | 0.00% |
| Cash Payout Ratio | 0.00% |
| Consistent Payer (5Y) | No |
| Consistent Growth (5Y) | No |
Risk Info
Total Returns Comparison
Annual Total Returns Versus Peers
As of October 05, 2022.
Fundamentals
| Revenue (TTM) | 884.24M |
| Total Expenses (TTM) | 1.599B |
| Net Income (TTM) | -980.72M |
| Total Assets (Quarterly) | 3.330B |
| Total Liabilities (Quarterly) | 3.154B |
| Shareholders Equity (Quarterly) | 176.04M |
| Cash from Operations (TTM) | -578.19M |
| Cash from Investing (TTM) | -506.30M |
| Cash from Financing (TTM) | 931.42M |
Ratings
Profile
Edit
| Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships. |
| URL | https://www.alnylam.com |
| Investor Relations URL | https://investors.alnylam.com/ |
| HQ State/Province | Massachusetts |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | Mid Cap/Growth |
| Next Earnings Release | Oct. 28, 2022 (est.) |
| Last Earnings Release | Jul. 28, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Risk Info
Ownership
| Insider Ownership Percentage | Upgrade |
Jul '20
Nov '20
Mar '21
80.00%
40.00%
10.00%
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Top Fund Holders
| Symbol | Dollars Invested | % Weight |
|---|---|---|
| FBT | 60.99M USD | 4.65% |
| FBIOX | 172.68M USD | 3.42% |
| IBB | 190.29M USD | 2.56% |
| QQQJ | 15.75M USD | 2.08% |
| FXH | 23.84M USD | 1.64% |
| VGHCX | 734.54M USD | 1.62% |
| THISX | 205.48M USD | 1.32% |
| FOCKX | 261.95M USD | 1.22% |
| FGCKX | 471.97M USD | 1.08% |
| XT | 22.46M USD | 0.82% |
| VEXMX | 339.48M USD | 0.40% |
| VXF | 339.48M USD | 0.40% |
Other Resources
| Whale Wisdom | 13F Filings |
| Seeking Alpha | Call Transcripts |
| Morningstar | Insider Trading |
| Nasdaq | Institutional Ownership |
| Nasdaq | Option Chain |
| SEC | SEC Filings |
| ALNY Tweets |